Skip to main content
logo
Cellromax Science Co., Ltd. (KOSDAQ:471820)
South Korea flag South Korea · Delayed Price · Currency is KRW
4,065.00
-40.00 (-0.97%)
At close: Sep 1, 2026

Cellromax Science Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024
Period EndingJun '26 Dec '25 Dec '24
Revenue
19,60422,18421,630
Revenue Growth
-16.01%2.56%-
Gross Profit
9,81410,54712,284
Operating Income
2,1532,8355,501
Net Income
3,0682,9663,817
Earnings Per Share
273.02261.00367.00
EPS Growth
41.33%-28.88%-

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024
Period EndingJun '26 Dec '25 Dec '24
Cash & Investments
9,4247,70322,732
Total Debt
306.11477.831,498
Net Cash (Debt)
9,1187,22621,234
Net Cash Growth
-24.86%-65.97%-
Net Cash Per Share
808.43633.292041.44

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024
Period EndingJun '26 Dec '25 Dec '24
Operating Cash Flow
2,1751,7856,294
Capital Expenditures
-48.91-78.64-206.22
Free Cash Flow
2,1261,7076,088
Free Cash Flow Growth
-48.28%-71.97%-

Margins
Chart
Fiscal YearTTMFY 2025FY 2024
Period EndingJun '26 Dec '25 Dec '24
Gross Margin
50.06%47.54%56.79%
Operating Margin
10.98%12.78%25.43%
Pretax Margin
14.00%15.56%23.75%
Profit Margin
15.65%13.37%17.65%
FCF Margin
10.84%7.69%28.15%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024
Period EndingSep '26 Dec '25 Dec '24
PE Ratio
14.9324.8014.99
P/FCF Ratio
21.1643.119.40
PS Ratio
2.303.322.65